Observational studyJournal of Huntington's disease2013
Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.
Observational study in Journal of Huntington's disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study.Brain and behavior · 2026Observational
- Exploring huntington's disease from a neurodevelopmental perspective.International journal of biological sciences · 2026Review
- Brain organoid models of Huntington's disease shift the focus towards neurodevelopment.Disease models & mechanisms · 2025Article
- Huntingtin CAG repeat size variations below the Huntington's disease threshold: associations with depression, anxiety and basal ganglia structure.European journal of human genetics : EJHG · 2025Article
- Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease.Brain communications · 2023Article
- Article
- Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white matter and grey matter volume with increasing dose.Clinical and translational radiation oncology · 2021Article
- svReg: Structural varying-coefficient regression to differentiate how regional brain atrophy affects motor impairment for Huntington disease severity groups.Biometrical journal. Biometrische Zeitschrift · 2021Article
- Decreased Basal Ganglia Volume in Cerebral Amyloid Angiopathy.Journal of stroke · 2021Article
- Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.Frontiers in neurology · 2021Review
- Dose-dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy.Clinical and translational radiation oncology · 2021Article
- The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy.Aging and disease · 2020Review
- SeSBAT: Single Subject Brain Analysis Toolbox. Application to Huntington's Disease as a Preliminary Study.Frontiers in systems neuroscience · 2020Article
- Structural neuroimaging differentiates vulnerability from disease manifestation in colombian families with Huntington's disease.Brain and behavior · 2019Article
- Repeat-associated non-AUG (RAN) translation: insights from pathology.Laboratory investigation; a journal of technical methods and pathology · 2019Review
- Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.Journal of neurology · 2019Review
- Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease.NeuroImage. Clinical · 2019Article
- Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease.Frontiers in neurology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD).
objectiveDemonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures.
methodsMeasures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD.
resultsCaudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures.
conclusionsResults of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.